
As the largest hospital in the Middle East, Israel’s Sheba Medical Center has been ranked top 10 of World’s Best Hospital and World’s Best Smart Hospitals by “Newsweek.”
As the Authorised Representative of Sheba Global, the outreaching arm of Sheba Medical Center, we look forward to building mutually beneficial strategic partnerships with leading medical institutes, healthcare organizations, insurance companies in Hong Kong, Macau, the Great Bay Area (GBA) and other areas of China. We are ready to bring comprehensive knowledge, R & D breakthroughs, and novel technologies with us into partnership building.



On 28th November 2025, A landmark collaboration was established, bringing together three global leaders across healthcare, technology, and research: Tech giant NVDIA, Sheba Medicial Center's ARC and Icahn School of Medicine at Mount Sinai.
What could the 98% of our DNA, once dismissed as "junk", reveal about our health?
For the first time in human history, leading experts from NVDIA, Sheba Medical Center's ARC, and Icahn School of Medicine at Mount Sinai have joined forces to decode the unexplored genomic territory through the application of large language model (LLM) technology.
Together, they are uniting to unlock one of the most consequential frontiers in modern medicine through advanced AI-driven genomic discovery, advancing a future of more precise, patient-centered care worldwide.

A multidisciplinary team of researchers and physicians at Sheba Medical Center has developed a personalized RNA-based therapy for an 8-year-old patient suffering from a rare neurodevelopment disorder caused by a mutation in the GNAO1gene. This marks the first time in Israel - and one of the few instances worldwide - where a customized genetic drug has been created specifically for a patient, designed to precisely modulate the expression of the defective gene.
The disorder, known as GNAO1-neurodevelopmental disorder, causes severe developmental delays, involuntary movements, and sometimes seizures. Until now, there has been no available drug treatment for the disease, only symptomatic therapies.
The drug developed at Sheba is based on Antisense Oligonucleotide (ASO) technology - short nucleic acid molecules capable of "silencing" the defective and toxic copy of the gene, thereby restoring cellular balance. The researchers created a library of dozens of different ASO molecules, testing their effectiveness and specific impact in cell models derived from the patient. Ultimately, the identified one ASO molecule with a specific sequence that successfully reduced expression of the defective gene and restored normal neuronal function.

Israeli scientist Prof. Benjamin Dekel and his team at Shema Tel HaShomer Medical Center and Tel Aviv University have grown human kidney organoids for more than 34 weeks that mirror fetal kidney development successfully. This world-first breakthrough allows researchers to study kidney diseases, test drug toxicity, and explore new regenerative treatments in ways never possible before.
In an interview with South China Moring Post in HongKong, Prof. Dekel expressed interest in collaborating with biotech partners in China and Hong Kong who focus on tackling chronic kidney diseases. For more information about the research breakthrough and potential cooperation, please feel free to contact NBI Solutions, the representative in Hong Kong.

Look far and plan ahead. Join the world top hospital pioneering in virtual healthcare to create innovative and better solutions for tomorrow.

Public knowledge promotion, prevention, solutions in the filed of mental health are becoming more urgent. Post-Pendemic era, growing pain for teenagers, social stress and work demands, all could be the source of a miserable or hopeless life. Getting insights in mental well-being, noticing mental health needs timely and receiving quality assistance and care are invaluable for everyday life.
